NFKB1 and chronic obstructive pulmonary disease: In ALI, COPD, asthma, PAH and PF, FMN consistently has dual effects: enhancing the antioxidant Nrf2/HO-1 pathway and suppressing NF-κB–mediated cytokine activity.